and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to drive increased sales of Dupixent, which is approved for a range of ...
Zacks.com on MSN3mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary GoalsBesides Dupixent, Nucala faces strong competition ... AZN is also evaluating Fasenra in late-stage studies for treating nasal ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, among others. The growth runway has not yet run its course. In September 2024, DUPIXENT was approved by the FDA for treatment of ...
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback